Supplemental material
Future Oncology
Volume 14, 2018 - Issue 21
Open access
9,512
Views
58
CrossRef citations to date
0
Altmetric
Clinical Trial Protocol
Avelumab (Anti-PD-L1) in Platinum-Resistant/Refractory Ovarian Cancer: JAVELIN Ovarian 200 Phase III Study Design
Eric Pujade-Lauraine1 Hôpital Hôtel-Dieu, Centre des Cancers de la Femme et Recherche Clinique, AP-HP, Université Paris Descartes, Paris, FranceCorrespondence[email protected]
View further author information
, View further author information
Keiichi Fujiwara2 Saitama Medical University International Medical Center, Saitama, JapanView further author information
, Samuel S Dychter3 Pfizer Oncology, La Jolla, CA92121, USAView further author information
, Geeta Devgan4 Pfizer Oncology, New York, NY10017, USAView further author information
& Bradley J Monk5 Arizona Oncology (US Oncology Network), University of Arizona & Creighton University, Phoenix, AZ85016, USAView further author information
Pages 2103-2113
|
Received 24 Jan 2018, Accepted 09 Mar 2018, Published online: 27 Mar 2018
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.